MET and cancer: Gatekeeper or solvent front mutations frequently pose a liability for targeted kinase inhibitors, for example, ALK (ALKG1202R) and ROS1 (ROS1G2032R) recurrently arise in cancer patients treated with crizotinib, a type I ROS1/ALK/MET targeted TKI25,35,36.